Drug Trial Radar · NCT04315272
Gut and Azithromycin Mechanisms in Infants and Children II
Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
449
Actual
Start
Aug 21, 2020
Primary completion
Jun 1, 2022
Study completion Jun 1, 2022
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centre de Recherche en Sante de Nouna, Burkina Faso
- First posted
- Mar 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 days, up to 59 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Childhood mortality is decreasing worldwide. However, many sub-Saharan countries still have high children under 5 mortality rates. The MORDOR trial in Niger, Tanzania, and Malawi demonstrated a near 14% decrease in all-cause child mortality following biannual azithromycin in children 1-59 months. Current trials in Burkina aim to replicate these results from the MORDOR study with mass azithromycin treatment. The investigators conducted an individually randomized placebo-controlled trial in Burkina Faso called the Gut and Azithromycin Mechanisms in Infants and Neonates Trial (GAMIN: NCT03676751) to evaluate the effect of a single dose of azithromycin (20 mg/kg) on potential mediators of the effect of azithromycin on all-cause mortality and to evaluate changes in the gut microbiome longitudinally (results pending). Here, the investigators propose to conduct an expansion of the original GAMIN trial. In GAMIN II, the investigators will evaluate 450 additional 1-59 month old children longitudinally for 6 months with a focus on stool collection and malaria status. Objectives: 1\. To determine the effect of a single dose of azithromycin for children aged 8 days-59 months on malaria. The investigators hypothesize that a single dose of azithromycin will result in a reduced malaria status within the treatment group compared to the placebo group after a 14 day period within children ages 8 days-59 months. The study will be conducted in Nouna Town in northwestern Burkina Faso.
Conditions
- Malaria
Interventions
AzithromycinDrug
Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Malaria StatusTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre de Recherche en santé de nouna
Nouna, Boucle du Mouhoun, Burkina Faso
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.